Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) posted its earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.33, FiscalAI reports. The business had revenue of $3.17 million for the quarter, compared to analyst estimates of $0.45 million. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%.
Armata Pharmaceuticals Price Performance
Shares of ARMP traded down $0.17 on Thursday, hitting $3.72. The company’s stock had a trading volume of 105,066 shares, compared to its average volume of 119,327. The company has a market capitalization of $138.31 million, a PE ratio of -0.49 and a beta of 1.54. Armata Pharmaceuticals has a fifty-two week low of $2.74 and a fifty-two week high of $14.98. The company has a 50 day moving average price of $3.83 and a 200 day moving average price of $6.86.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Armata Pharmaceuticals in a report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.00.
Get Our Latest Stock Report on ARMP
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals is a clinical-stage biotechnology company developing bacteriophage-based treatments for bacterial infections. Bacteriophages are viruses that infect and kill specific bacteria, and Armata’s approach is intended to target disease-causing bacteria, including strains that are difficult to treat with antibiotics. The company’s development programs have included AP-PA02, an inhaled phage therapy being studied for Pseudomonas aeruginosa lung infections, and AP-SA02, an intravenous therapy targeting Staphylococcus aureus infections.
Read More
- Five stocks we like better than Armata Pharmaceuticals
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
